Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International N.V
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease
The primary objectives are: - To evaluate clinical remission for the 2 SC maintenance regimens of ustekinumab in subjects with moderately to severely active Crohn’s disease induced into clinical resp...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
JANSSEN-CILAG CR013165 : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance de trois schémas thérapeutiques de deuxième ligne, avec du bortézomib et de la dexaméthasone associés ou non à de la cyclophosphamide ou du lénalidomide, chez des patients ayant un myélome multiple. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Efficacy and safety of velcade plus dexamethasone (VD), VD+cyclophosphamide or VD plus lenalidomide in MMY patients who are refractory or have relapsed after their primary therapy for MMY and have ach...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult subjects with attent...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Estudio de la eficacia y seguridad de risperidona en el tratamiento de adolescentes con esquizofrenia: Estudio abierto de seis meses
Valorar la eficacia y seguridad de risperidona a lo largo de 6 meses de tratamiento en adolescentes con esquizofrenia
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma
To compare the efficacy of daratumumab when combined with VELCADE and dexamethasone (DVd) to that of VELCADE and dexamethasone (Vd), in terms of progression-free survival (PFS) in subjects with relaps...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
CR103663 : Essai de phase 3 randomisé, évaluant l’efficacité du lénalidomide et de la dexaméthasone associé ou non au daratumumab, chez des patients ayant un myélome multiple en rechute ou réfractaire. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de l’association du lénalidomide, de la dexaméthasone et du daratumumab, chez des patients ayant un myélome multiple en rechute ou réfractaire. Les ...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Study to compare 2 treatment strategies in Crohn's Disease patients treated with Ustekinumab Estudio para comparar 2 estrategias de tratamiento en pacientes con enfermedad de Crohn tratados con Ustekinumab
To evaluate the efficacy of a treat to target strategy coupled with early endoscopic assessment versus a clinically driven (routine care) approach in achieving endoscopic response. Evaluar la ef...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
5
6
7
8
9
10